Overview: NGS Leukodystrophy Panel Sequencing TestIntroduction: The NGS Leukodystrophy Panel Sequencing Test sequences genes to diagnose leukodystrophy, causing neurological decline. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected leukodystrophies, such as metachromatic leukodystrophy.
Other Names: Leukodystrophy NGS Assay, Leukodystrophy Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Leukodystrophy sequencing began in the 1990s with white matter disease research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose leukodystrophy, guides treatment, and evaluates patients with neurological decline.
Test Parameters: 1. Leukodystrophy Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of neurological decline, spasticity, or leukodystrophy symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document neurological decline, spasticity, cognitive issues, or family history of leukodystrophy. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, leukodystrophy implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze leukodystrophy genes (e.g., ARSA, GALC). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for leukodystrophy diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm leukodystrophy, guiding supportive care or gene therapy trials. Negative results may require brain MRI.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, CSF analysis, or enzyme testing to confirm leukodystrophy diagnosis.
Test Limitations: Not all leukodystrophy cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Leukodystrophy Guidelines, 2023; Neurology, van der Knaap MS, 2022.
